https://saudigazette.com.sa/article/622943
Chardan Capital Reiterates Buy on PLBY Group, Maintains $5 Price Target
Chardan Capital analyst Brian Dobson reiterates PLBY Group (NASDAQ:PLBY) with a Buy and maintains $5 price target.
Related Posts
Five New Ohio Online Sports Betting Operators Approved For Jan. 1 Launch
he Ohio Casino Control Commission approved its next batch of sports betting license and Ohio online sports betting operators ahead of the rapidly approaching Jan. 1 universal launch.
The casino control
FDA Approves Irinotecan Liposome For First-line Treatment Of Metastatic Pancreatic Adenocarcinoma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinomaOn February 13, 2024, the Food and Drug Administration approved
Atai Update: Ketamine Trials Are Ongoing, Company Cuts 30% Workforce
The clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) founded in 2018 shared updates on the two clinical trials as well as its plan to streamline its workforce with significant layoffs.